Factors associated with immunotherapy selection in patients with advanced melanoma

Richard W. Joseph, Alicia C. Shillington, Cynthia Macahilig, Scott J. Diede, Vaidehi Dave, Qing Harshaw, Frank Xiaoqing Liu

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Aim: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. Materials & methods: Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice. Results: Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2–4 versus 0–1 (odds ratio [OR]: 6.6; 95% CI: 3.0–14.7), if they were PD-L1 positive (OR: 4.5; 95% CI: 1.9–10.4) or had BRAF wild-type tumor (OR: 2.2; 95% CI: 1.4–3.6). Conclusion: Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.

Original languageEnglish (US)
Pages (from-to)1361-1369
Number of pages9
Issue number16
StatePublished - 2018


  • Advanced melanoma
  • Immunotherapy
  • Ipilimumab
  • Nivolumab
  • Pembrolizumab
  • Real-world study
  • Treatment selection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Factors associated with immunotherapy selection in patients with advanced melanoma'. Together they form a unique fingerprint.

Cite this